Inovio Pharmaceuticals Prices $20 Million Public Offering

Inovio Pharmaceuticals is raising $20 million through a public offering of common stock and warrants, the company announced Tuesday. The Plymouth Meeting-based biotech firm, which specializes in DNA medicines for HPV-related diseases and cancer, finalized the deal at a combined price of $0.95 per share and warrant.

Money Talk·July 30, 2026·reads: 259

The offering includes 21,052,632 shares of common stock alongside warrants to purchase up to 42,105,264 additional shares. These warrants carry an exercise price of $1.10 per share. Piper Sandler is serving as the sole manager for the transaction, which is expected to close around July 31, 2026, pending standard closing conditions.

In addition to the primary sale, the underwriters hold a 30-day option to purchase an extra 3,157,894 shares and warrants to cover over-allotments. The company intends to use the capital to support its ongoing development of DNA medicine platforms. The securities were sold under a shelf registration statement declared effective by the SEC on July 10.